The cardiac safety of trastuzumab in the treatment of breast cancer

Bibliography

• Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5(1):63-9
   PubMedGoogle Scholar
• Slamon DJ, Clark GM, Wong SG, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Lane HA, Beuvink I, Motoyama AB, ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000;20(9):3210-23
   PubMed Web of Science ®Google Scholar
• Longva KE, Pedersen NM, Haslekas C, Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005;116(3):359-67
   PubMed Web of Science ®Google Scholar
• Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007;26(46):6577-92
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6(2):117-27
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18(6):977-84
   PubMed Web of Science ®Google Scholar
• Klos KS, Zhou X, Lee S, Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003;98(7):1377-85
   PubMed Web of Science ®Google Scholar
• Petit AM, Rak J, Hung MC, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151(6):1523-30
   PubMed Web of Science ®Google Scholar
• Viloria-Petit A, Crombet T, Jothy S, Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61(13):5090-101
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89(10):4285-9
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6(4):443-6
   PubMed Web of Science ®Google Scholar
• Kubo M, Morisaki T, Kuroki H, Combination of adoptive immunotherapy with herceptin for patients with HER2-expressing breast cancer. Anticancer Res 2003;23(6a):4443-9
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J cancer 2006;94(2):259-67
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10(17):5650-5
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639-48
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castaneda-Soto NJ, Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23(10):2162-71
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26
   PubMed Web of Science ®Google Scholar
• Pegram MD, Konecny GE, O'Callaghan C, Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96(10):739-49
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23(19):4265-74
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Harris LN, Marcom PK, Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21(15):2889-95
   PubMed Web of Science ®Google Scholar
• Chan A, Martin M, Untch M, Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 2006;95(7):788-93
   PubMed Web of Science ®Google Scholar
• Jahanzeb M, Mortimer JE, Yunus F, Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002;7(5):410-7
   PubMed Web of Science ®Google Scholar
• Bartsch R, Wenzel C, Altorjai G, Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25(25):3853-8
   PubMed Web of Science ®Google Scholar
• Schaller G, Fuchs I, Gonsch T, Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007;25(22):3246-50
   PubMed Web of Science ®Google Scholar
• Xu L, Song S, Zhu J. A phase II trial of trastuzumab (H) + capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer. J Clin Oncol 2006 ASCO Ann Meet Proc Part 1 2006;24(18S):10615
   Google Scholar
• Brufsky AK, Fox K, Orlando M, Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression. J Clin Oncol 2006 ASCO Ann Meet Proc Part I 2006;24(18S):10591
   Google Scholar
• O'Shaughnessy JA, Vukelja S, Marsland T, Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004;5(2):142-7
   PubMedGoogle Scholar
• Perez EA, Romond E, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007;25(Suppl 18):512
   Google Scholar
• Smith I, Procter M, Gelber RD, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369(9555):29-36
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N PT, BCIRG 006 Phase III Trial Comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. Cancer Res 2009;29: abstract 62
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20
   PubMed Web of Science ®Google Scholar
• Spielmann M, Roche H, Delozier T, Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27(36):6129-34
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson NE, Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 2009;29: abstract 80
   Google Scholar
• Lee KF, Simon H, Chen H, Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378(6555):394-8
   PubMed Web of Science ®Google Scholar
• Crone SA, Zhao YY, Fan L, ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8(5):459-65
   PubMed Web of Science ®Google Scholar
• Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004;59:1-12
   PubMedGoogle Scholar
• Ozcelik C, Erdmann B, Pilz B, Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 2002;99(13):8880-5
   PubMed Web of Science ®Google Scholar
• Ueda H, Oikawa A, Nakamura A, Neuregulin receptor ErbB2 localization at T-tubule in cardiac and skeletal muscle. J Histochem Cytochem 2005;53(1):87-91
   PubMed Web of Science ®Google Scholar
• Chien KR. Herceptin and the heart–a molecular modifier of cardiac failure. N Engl J Med 2006;354(8):789-90
   PubMed Web of Science ®Google Scholar
• Levine MN. Trastuzumab cardiac side effects: only time will tell. J Clin Oncol 2005;23(31):7775-6
   PubMed Web of Science ®Google Scholar
• Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol 2003;30(5 Suppl 16):49-53
   PubMed Web of Science ®Google Scholar
• Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 2001;28(5 Suppl 16):18-26
   PubMed Web of Science ®Google Scholar
• Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000;275(43):33585-92
   PubMed Web of Science ®Google Scholar
• Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987;19(8):817-28
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339(13):900-5
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997;11(12):931-6
   PubMed Web of Science ®Google Scholar
• Sinha BK, Katki AG, Batist G, Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol 1987;36(6):793-6
   PubMed Web of Science ®Google Scholar
• Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999;274(8):5038-46
   PubMed Web of Science ®Google Scholar
• Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980;65(1):128-35
   PubMed Web of Science ®Google Scholar
• Dowd NP, Scully M, Adderley SR, Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001;108(4):585-90
   PubMed Web of Science ®Google Scholar
• Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004;13(3):173-83
   PubMed Web of Science ®Google Scholar
• Ewer MS, Vooletich MT, Durand JB, Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6
   PubMed Web of Science ®Google Scholar
• Guarneri V, Lenihan DJ, Valero V, Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J Clin Oncol 2006;24(25):4107-15
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson NE, Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26(8):1231-8
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK, Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21
   PubMed Web of Science ®Google Scholar
• Seidman AD, Fornier MN, Esteva FJ, Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19(10):2587-95
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E, Yothers G, Romond E, Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9
   PubMed Web of Science ®Google Scholar
• Rastogi P, Jeong J, Geyer CE, Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) →paclitaxel (T) vs. AC → T with trastuzumab (H). J Clin Oncol 2007;25(18S):LBA513
   Google Scholar
• Sledge GW, O'Neill A, Thor A, Adjuvant trastuzumab: long-term results of E2198. Breast Cancer Res Treat 2007;100(Suppl 1):2075
   Google Scholar
• Buzdar AU, Valero V, Ibrahim NK, Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13(1):228-33
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V, Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Cancer Res 2009;69(Suppl 2):31
   Google Scholar
• Gianni L, Semiglazov V, Manikhas GM, Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. J Clin Oncol 2007;25(18S):532
   PubMedGoogle Scholar
• Halyard MY, Pisansky TM, Solin LJ, Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol 2006;24(18S):523
   PubMedGoogle Scholar
• Geyer CE, Forster J, Lindquist D, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
   PubMed Web of Science ®Google Scholar
• Perez EA, Koehler M, Byrne J, Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83(6):679-86
   PubMed Web of Science ®Google Scholar
• Cortés J, Baselga J, Petrella T, Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2- positive breast cancer. J Clin Oncol 2009;27(15S):1022
   Google Scholar
• Gelmon KA, Fumoleau P, Verma S, Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 2008;26:1026
   Web of Science ®Google Scholar
• Vogel CL, Burris HA, Limentani S, A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. J Clin Oncol;27(15S):1017
   Google Scholar
• Swaby R, Blackwell K, Jiang Z, Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol;27(15S):1004
   Google Scholar
• Migliaccio I GM, Wu M-F, Wong H, PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). Cancer Res 2009;69(Suppl 2):34
   Google Scholar
• Blackwell K, Burstein HJ, Sledge G, Updated Survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer 2009;29: abstract 61
   Google Scholar
• Epstein M, Ayala R, Tchekmedian N, Borgstrom P, HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2002;76:S143
   Web of Science ®Google Scholar
• Konecny GE, Meng YG, Untch M, Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10(5):1706-16
   PubMed Web of Science ®Google Scholar
• Yen L, You XL, Al Moustafa AE, Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19(31):3460-9
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Pegram MD, Lin L-S, Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res 2009;29: abstract 6094
   Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66(13):6732-40
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8(4):1172-81
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res 2007;24(12):2402-11
   PubMed Web of Science ®Google Scholar